Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.71 |
| ▸ | TACR1 | P25103 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184939 | 1.00 | KMT2A (0.71) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL29401459 | 1.00 | KMT2A (0.71) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL29138492 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL16626132 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL6362124 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL6355051 | 0.90 | TACR1 (0.63) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL850315 | 0.90 | TACR1 (0.74) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL3185689 | 0.90 | TACR1 (0.74) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL5385762 | 0.90 | TACR1 (0.72) | KMT2AMEN1HCRTR1TACR1MAPT | |
| SCHEMBL30359404 | 0.90 | TACR1 (0.72) | KMT2AMEN1HCRTR1TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | claimed |
| EP-4345104-B1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-08-28 | — | — | EP | claimed |
| WO-2024068827-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-04-04 | — | — | WO | claimed |
| EP-4345104-A1 | METHOD FOR PREPARING LIRAGLUTIDE | Bachem Holding AG (CH) | 2024-04-03 | — | — | EP | claimed |
| EP-1428537-B1 | STABILIZED PREPARATIONS CONTAINING ANTIBODY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-11-19 | — | — | EP | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | disclosed |
| US-20240316223-A1 | Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-26 | — | — | US | disclosed |
| EP-4345104-B1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024068827-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-04-04 | — | — | WO | disclosed |
| EP-4345104-A1 | METHOD FOR PREPARING LIRAGLUTIDE | Bachem Holding AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1260230-A1 | PREPARATIONS STABILIZED OVER LONG TIME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-11-27 | — | — | EP | disclosed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | disclosed |
| US-4761233-A | Novel membranes and process for making them | MEMBRANE PRODUCTS KIRYAT WEIZMANN LTD. (IL) | 1988-08-02 | — | — | US | disclosed |
| EP-0238276-A2 | Novel membranes and process for making them | MEMBRANE PRODUCTS KIRYAT WEIZMANN LTD. (IL) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486300-B2 | Mithramycin oxime derivatives having increased selectivity and anti-cancer activity | TFAM, HSPE1, PRDX3 | KMT2A 696/4885MEN1 153/4885HCRTR1 3348/4885 |
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | GLP1R, IAPP, VIP | KMT2A 2447/4885MEN1 610/4885HCRTR1 1502/4885 |
| US-20240316223-A1 | Oxidative Cyclization Reagents for Chemoselective Tryptophan Bioconjugation | TDO2, TPH1, TPH2 | KMT2A 2305/4885MEN1 3689/4885HCRTR1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.